NYSE:AORT

Artivion (AORT) Stock Price, News & Analysis

$20.32
+0.29 (+1.45%)
(As of 04/22/2024 ET)
Today's Range
$20.00
$20.46
50-Day Range
$17.03
$21.64
52-Week Range
$12.16
$21.90
Volume
122,028 shs
Average Volume
153,938 shs
Market Capitalization
$837.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.50

Artivion MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
15.6% Upside
$23.50 Price Target
Short Interest
Bearish
7.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.26mentions of Artivion in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.89 M Sold Last Quarter
Proj. Earnings Growth
123.08%
From $0.26 to $0.58 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.53 out of 5 stars

Medical Sector

670th out of 909 stocks

Surgical & Medical Instruments Industry

75th out of 97 stocks

AORT stock logo

About Artivion Stock (NYSE:AORT)

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

AORT Stock Price History

AORT Stock News Headlines

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Artivion VP regulatory sells shares worth $79,880
Artivion executive sells shares worth nearly $100k
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
AORT Apr 2024 12.500 put
Artivion's Earnings: A Preview
Artivion Inc AORT
Stifel Nicolaus Reaffirms Their Buy Rating on Artivion (AORT)
See More Headlines
Receive AORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/22/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Employees
1,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.50
High Stock Price Target
$25.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+15.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-30,690,000.00
Pretax Margin
-6.10%

Debt

Sales & Book Value

Annual Sales
$354.00 million
Cash Flow
$0.78 per share
Book Value
$6.87 per share

Miscellaneous

Free Float
37,863,000
Market Cap
$837.18 million
Optionable
Optionable
Beta
1.67
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. James Patrick Mackin (Age 57)
    Chairman, President & CEO
    Comp: $1.63M
  • Ms. Jean F. Holloway Esq. (Age 67)
    Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
    Comp: $636.72k
  • Mr. John E. Davis (Age 59)
    Senior VP & Chief Commercial Officer
    Comp: $609.91k
  • Dr. Marshall S. Stanton M.D. (Age 67)
    Senior VP of Clinical Research & Chief Medical Officer
    Comp: $615.55k
  • Ms. Amy D. Horton CPA (Age 54)
    VP & Chief Accounting Officer
  • Mr. Matthew A. Getz (Age 55)
    VP of Human Resources & Chief Human Resources Officer
  • Dr. Robert C. Thomson (Age 54)
    Vice President of Research & Development
  • Mr. Florian Tyrs
    Vice President of Global Operations

AORT Stock Analysis - Frequently Asked Questions

Should I buy or sell Artivion stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Artivion in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AORT shares.
View AORT analyst ratings
or view top-rated stocks.

What is Artivion's stock price target for 2024?

2 Wall Street analysts have issued 1 year target prices for Artivion's stock. Their AORT share price targets range from $22.00 to $25.00. On average, they anticipate the company's stock price to reach $23.50 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
View analysts price targets for AORT
or view top-rated stocks among Wall Street analysts.

How have AORT shares performed in 2024?

Artivion's stock was trading at $17.88 on January 1st, 2024. Since then, AORT shares have increased by 13.6% and is now trading at $20.32.
View the best growth stocks for 2024 here
.

When is Artivion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AORT earnings forecast
.

How were Artivion's earnings last quarter?

Artivion, Inc. (NYSE:AORT) issued its quarterly earnings results on Thursday, February, 15th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.24. The firm had revenue of $93.67 million for the quarter, compared to the consensus estimate of $89.75 million. Artivion had a positive trailing twelve-month return on equity of 3.02% and a negative net margin of 8.67%.

What ETFs hold Artivion's stock?
What guidance has Artivion issued on next quarter's earnings?

Artivion issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $382.0 million-$396.0 million, compared to the consensus revenue estimate of $384.3 million.

Who are Artivion's major shareholders?

Artivion's stock is owned by a number of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (2.63%), Mesirow Financial Investment Management Inc. (0.03%), Allspring Global Investments Holdings LLC (0.01%), Register Financial Advisors LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Amy Horton, Andrew M Green, David Ashley Lee, Dennis B Maier, James P Mackin, Jean F Holloway, John E Davis, Marshall S Stanton, Matthew A Getz and Rochelle L Maney.
View institutional ownership trends
.

How do I buy shares of Artivion?

Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:AORT) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners